A prospective, multicenter, observational study of the effects of SGLT2 inhibitors/ SPPARMalpha combination therapy on liver function in patients with type 2 diabetes and dyslipidemia
Not Applicable
Recruiting
- Conditions
- type 2 diabetes and dyslipidemia
- Registration Number
- JPRN-UMIN000043716
- Lead Sponsor
- niversity of Miyazaki
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with contraindications to SGLT2 inhibitors and/or pemafibrate 2. Patients receiving SGLT2 inhibitors and/or pemafibrate 3. Patients who judged unsuitable for this study by the investigator
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in ALT from baseline at 52 weeks post-treatment
- Secondary Outcome Measures
Name Time Method